Allegheny Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31.6K	Hold	20,000	–	–	﹤0.01%	289
2025 Q4	$33.4K	Hold	20,000	–	–	﹤0.01%	285
2025 Q3	$33.8K	Hold	20,000	–	–	0.01%	262
2025 Q2	$18.1K	Hold	20,000	–	–	﹤0.01%	247
2025 Q1	$9.03K	Hold	20,000	–	–	﹤0.01%	230
2024 Q4	$10.1K	Hold	20,000	–	–	﹤0.01%	229
2024 Q3	$18.1K	Hold	20,000	–	–	﹤0.01%	240
2024 Q2	$19.9K	Hold	20,000	–	–	0.01%	219
2024 Q1	$29.6K	Hold	20,000	–	–	0.01%	203
2023 Q4	$21.8K	Hold	20,000	–	–	0.01%	208
2023 Q3	$23.6K	Buy	+20,000	New	+$27.2K	0.01%	190
2023 Q2	–	Sell	-20,000	Closed	-$30K	–	157
2023 Q1	$30K	Hold	20,000	–	–	0.01%	161
2022 Q4	$23.4K	Hold	20,000	–	–	0.01%	165
2022 Q3	$22K	Hold	20,000	–	–	0.01%	156
2022 Q2	$32K	Hold	20,000	–	–	0.01%	163
2022 Q1	$31K	Hold	20,000	–	–	0.01%	159
2021 Q4	$49K	Hold	20,000	–	–	0.02%	156
2021 Q3	$50K	Hold	20,000	–	–	0.02%	150
2021 Q2	$57K	Hold	20,000	–	–	0.03%	152
2021 Q1	$47K	Hold	20,000	–	–	0.03%	101
2020 Q4	$35K	Buy	+20,000	New	+$28K	0.02%	130

Other funds holding LCTX